Developer docs
API playgroundTry for free, no card

Search company profiles

Pentixapharm

Full company profile

uuid0000s9f

Namestring
Pentixapharm
Legal namestring
Pentixapharm Holding AG
Company typeenum
Public
Founded yearint
2024
Descriptiontext

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical biotechnology company headquartered in Berlin, Germany, with a secondary office in Würzburg. Founded in 2019 and spun off from the Eckert & Ziegler Group, the company listed on the Frankfurt Stock Exchange Prime Standard (ticker: PTP) in October 2024 and is led by CEO Dr. Dirk Pleimes. Pentixapharm develops first-in-class CXCR4-targeted radiopharmaceuticals comprising a theranostic pair: [68Ga]Ga-PentixaFor, a gallium-68-labeled diagnostic used in PET/CT imaging, and [177Lu]Lu-PentixaTher / [90Y]Y-PentixaTher, therapeutic agents labeled with lutetium-177 or yttrium-90 for targeted radiotherapy. The lead clinical program is the FDA IND-cleared Phase 3 PANDA trial evaluating PentixaFor for non-invasive diagnosis of primary aldosteronism in approximately 270 patients, with FDA 'Study May Proceed' also secured for the PENTHERA Phase I/II trial in hemato-oncology (AML and multiple myeloma). A second platform, GT-008, targets CD24 with a glycan-dependent antibody radiopharmaceutical, acquired via the July 2024 purchase of Glycotope GmbH's target discovery business.

The company's commercial model is sales-led through radiopharmacy networks, imaging-company partnerships, and US-based commercial partners, targeting hospitals, cancer centers, and imaging centers with PET/CT infrastructure. Pentixapharm is pre-revenue from product sales, with LTM revenue of approximately $460,000 and €117 thousand for Q1-Q3 2025 likely reflecting minor licensing or collaboration receipts. Following an October 2025 organizational restructuring that reduced headcount at Pentixapharm AG by approximately 50% to roughly 80 employees (with over 80% focused on R&D), the company is concentrating resources on its late-stage clinical programs. Critical supply chain and manufacturing relationships include Eckert & Ziegler for isotope supply and ARRONAX (CHU Nantes) for radiopharmaceutical manufacturing, with clinical research conducted through the University Hospital of Nantes.

The company is funded through a combination of public equity and a planned 2026 rights-issue capital increase of up to €20 million, with major shareholder Eckert Wagniskapital und Frühphasenfinanzierung GmbH (~36% stake) committed to full subscription. BankM AG initiated coverage in June 2026 with a Buy rating and a €12.61 fair-value target. A BaFin financial reporting enforcement review of the 2024 consolidated financial statements is underway, with preliminary findings questioning EUR 34.7 million in intangible asset valuations, representing a governance overhang during a pivotal Phase 3 execution period.

Short descriptiontext

Pentixapharm is a clinical-stage German radiopharmaceutical biotech developing first-in-class CXCR4-targeted theranostic agents (PentixaFor for PET/CT diagnosis, PentixaTher for therapy) to address primary aldosteronism and hematological cancers, serving hospitals, cancer centers, and imaging centers via radiopharmacy distribution networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWürzburg, Germany
HQ citystring
Würzburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical development, theranostic imaging agents, CXCR4-targeted therapy, PET diagnostic imaging, radioligand therapeutics
Industry4 codes
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Radiopharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech. Future revenue expected from sales of radiopharmaceutical products through radiopharmacy networks upon regulatory approval. Potential licensing and partnership revenues.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1PentixaFor
Description

CXCR4-targeted gallium-68-labeled radiodiagnostic for PET/CT imaging, used in primary aldosteronism diagnosis and theranostic pairing

pentixapharm.com
+3 more records
Core offering1 text field

Pentixapharm is a clinical-stage biotech developing a CXCR4-targeted theranostic radiopharmaceutical pair: PentixaFor, a gallium-68 labeled diagnostic for PET/CT imaging (notably for non-invasive subtyping of primary aldosteronism), and PentixaTher, a lutetium-177 or yttrium-90 labeled therapeutic for CXCR4-expressing hematological malignancies. The portfolio also includes the GT-008 glycan-dependent anti-CD24 antibody radiopharmaceutical for solid tumors and a broader CXCR4 imaging platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pentixapharm is a clinical-stage biotech developing a portfolio of radiopharmaceuticals anchored by its CXCR4-targeted theranostic platform. The core products include [68Ga]Ga-PentixaFor (diagnostic PET/CT imaging agent) and [177Lu]Lu-PentixaTher/[90Y]Y-PentixaTher (therapeutic radiopharmaceuticals). The company has expanded into glycan-dependent antibody-based radiopharmaceuticals through the GT-008 program targeting CD24. The portfolio spans oncology (hematological cancers, solid tumors) and cardiology (primary aldosteronism diagnosis), with Phase 3 PANDA trial ongoing for cardiovascular diagnostic and Phase I/II trials in hemato-oncology.

Product and service4 records
1[68Ga]Ga-PentixaFor
CategoryRadiopharmaceutical diagnostic (PET imaging)
2[90Y]Y-PentixaTher
CategoryRadiopharmaceutical therapeutic
3[177Lu]Lu-PentixaTher
CategoryRadiopharmaceutical therapeutic
4GT-008
CategoryAntibody-based radiopharmaceutical therapeutic
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Acquisition of Glycotope GmbH's target discovery business in July 2024, providing access to additional targeting technologies and expanding Pentixapharm's pipeline capabilities in radiopharmaceutical development.

Strategic tierCoreTypeTechnology or Integration
Description

Isotope supply partnership for reliable sourcing of medical isotopes (gallium-68, lutetium-177, yttrium-90) required for radiopharmaceutical manufacturing. Critical supply chain partner.

3ARRONAX (CHU Nantes)
Strategic tierCoreTypeTechnology or Integration
Description

Manufacturing partnership with ARRONAX radiopharmacy at CHU Nantes for production of radiopharmaceutical products for clinical trials and eventual commercial supply.

4University Hospital of Nantes
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership for conducting studies on CXCR4-targeted radiopharmaceuticals. Provides clinical research capabilities, patient access, and scientific expertise for trial execution.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pentixapharm

Radiopharmaceuticalspentixapharm.com

Pentixapharm is a clinical-stage German radiopharmaceutical biotech developing first-in-class CXCR4-targeted theranostic agents (PentixaFor for PET/CT diagnosis, PentixaTher for therapy) to address primary aldosteronism and hematological cancers, serving hospitals, cancer centers, and imaging centers via radiopharmacy distribution networks.

What Pentixapharm does

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical biotechnology company headquartered in Berlin, Germany, with a secondary office in Würzburg. Founded in 2019 and spun off from the Eckert & Ziegler Group, the company listed on the Frankfurt Stock Exchange Prime Standard (ticker: PTP) in October 2024 and is led by CEO Dr. Dirk Pleimes. Pentixapharm develops first-in-class CXCR4-targeted radiopharmaceuticals comprising a theranostic pair: [68Ga]Ga-PentixaFor, a gallium-68-labeled diagnostic used in PET/CT imaging, and [177Lu]Lu-PentixaTher / [90Y]Y-PentixaTher, therapeutic agents labeled with lutetium-177 or yttrium-90 for targeted radiotherapy. The lead clinical program is the FDA IND-cleared Phase 3 PANDA trial evaluating PentixaFor for non-invasive diagnosis of primary aldosteronism in approximately 270 patients, with FDA 'Study May Proceed' also secured for the PENTHERA Phase I/II trial in hemato-oncology (AML and multiple myeloma). A second platform, GT-008, targets CD24 with a glycan-dependent antibody radiopharmaceutical, acquired via the July 2024 purchase of Glycotope GmbH's target discovery business.

The company's commercial model is sales-led through radiopharmacy networks, imaging-company partnerships, and US-based commercial partners, targeting hospitals, cancer centers, and imaging centers with PET/CT infrastructure. Pentixapharm is pre-revenue from product sales, with LTM revenue of approximately $460,000 and €117 thousand for Q1-Q3 2025 likely reflecting minor licensing or collaboration receipts. Following an October 2025 organizational restructuring that reduced headcount at Pentixapharm AG by approximately 50% to roughly 80 employees (with over 80% focused on R&D), the company is concentrating resources on its late-stage clinical programs. Critical supply chain and manufacturing relationships include Eckert & Ziegler for isotope supply and ARRONAX (CHU Nantes) for radiopharmaceutical manufacturing, with clinical research conducted through the University Hospital of Nantes.

The company is funded through a combination of public equity and a planned 2026 rights-issue capital increase of up to €20 million, with major shareholder Eckert Wagniskapital und Frühphasenfinanzierung GmbH (~36% stake) committed to full subscription. BankM AG initiated coverage in June 2026 with a Buy rating and a €12.61 fair-value target. A BaFin financial reporting enforcement review of the 2024 consolidated financial statements is underway, with preliminary findings questioning EUR 34.7 million in intangible asset valuations, representing a governance overhang during a pivotal Phase 3 execution period.

Pentixapharm firmographics

Firmographics
Name
Pentixapharm
Legal name
Pentixapharm Holding AG
Website
https://pentixapharm.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Pentixapharm is a clinical-stage German radiopharmaceutical biotech developing first-in-class CXCR4-targeted theranostic agents (PentixaFor for PET/CT diagnosis, PentixaTher for therapy) to address primary aldosteronism and hematological cancers, serving hospitals, cancer centers, and imaging centers via radiopharmacy distribution networks.
Ownership category
akta.pro rank

Pentixapharm industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radiopharmaceutical development
  • Theranostic imaging agents
  • CXCR4-targeted therapy
  • PET diagnostic imaging
  • Radioligand therapeutics

Where Pentixapharm is headquartered

Location

Headquarters

HQ city
Würzburg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Pentixapharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Radiopharmaceutical Product Sales: Pre-revenue clinical-stage biotech. Future revenue expected from sales of radiopharmaceutical products through radiopharmacy networks upon regulatory approval. Potential licensing and partnership revenues.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Pentixapharm product offering

Product offering

Core offering

Pentixapharm is a clinical-stage biotech developing a CXCR4-targeted theranostic radiopharmaceutical pair: PentixaFor, a gallium-68 labeled diagnostic for PET/CT imaging (notably for non-invasive subtyping of primary aldosteronism), and PentixaTher, a lutetium-177 or yttrium-90 labeled therapeutic for CXCR4-expressing hematological malignancies. The portfolio also includes the GT-008 glycan-dependent anti-CD24 antibody radiopharmaceutical for solid tumors and a broader CXCR4 imaging platform.

Product overview

Pentixapharm is a clinical-stage biotech developing a portfolio of radiopharmaceuticals anchored by its CXCR4-targeted theranostic platform. The core products include [68Ga]Ga-PentixaFor (diagnostic PET/CT imaging agent) and [177Lu]Lu-PentixaTher/[90Y]Y-PentixaTher (therapeutic radiopharmaceuticals). The company has expanded into glycan-dependent antibody-based radiopharmaceuticals through the GT-008 program targeting CD24. The portfolio spans oncology (hematological cancers, solid tumors) and cardiology (primary aldosteronism diagnosis), with Phase 3 PANDA trial ongoing for cardiovascular diagnostic and Phase I/II trials in hemato-oncology.

Differentiator

Problem solved

Functional benefit

Brands

  • PentixaFor: CXCR4-targeted gallium-68-labeled radiodiagnostic for PET/CT imaging, used in primary aldosteronism diagnosis and theranostic pairing
  • PentixaTher
  • GT-008
  • CXCR4-Targeted Imaging Platform

Products and services

  • [68Ga]Ga-PentixaFor
  • [90Y]Y-PentixaTher
  • [177Lu]Lu-PentixaTher
  • GT-008

Companies that use Pentixapharm

Customer profile

Segments3 records

Ideal customer profiles2 records

Pentixapharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pentixapharm partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Glycotope GmbHcoreStrategic or Co-development Partner · 1 July 2024Acquisition of Glycotope GmbH's target discovery business in July 2024, providing access to additional targeting technologies and expanding Pentixapharm's pipeline capabilities in radiopharmaceutical development.
  • Eckert & ZieglercoreTechnology or IntegrationIsotope supply partnership for reliable sourcing of medical isotopes (gallium-68, lutetium-177, yttrium-90) required for radiopharmaceutical manufacturing. Critical supply chain partner.
  • ARRONAX (CHU Nantes)coreTechnology or IntegrationManufacturing partnership with ARRONAX radiopharmacy at CHU Nantes for production of radiopharmaceutical products for clinical trials and eventual commercial supply.
  • University Hospital of NantescoreStrategic or Co-development PartnerClinical trial partnership for conducting studies on CXCR4-targeted radiopharmaceuticals. Provides clinical research capabilities, patient access, and scientific expertise for trial execution.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

Pentixapharm competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pentixapharm social profiles

Digital presence

Pentixapharm compliance and trust

Trust signal

Compliance1 record

Pentixapharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pentixapharm leadership team

Management profile

Number of profiles

Profiles5 records

Pentixapharm subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Pentixapharm funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pentixapharm M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pentixapharm

What does Pentixapharm do?

Pentixapharm is a clinical-stage biotech developing a CXCR4-targeted theranostic radiopharmaceutical pair: PentixaFor, a gallium-68 labeled diagnostic for PET/CT imaging (notably for non-invasive subtyping of primary aldosteronism), and PentixaTher, a lutetium-177 or yttrium-90 labeled therapeutic for CXCR4-expressing hematological malignancies. The portfolio also includes the GT-008 glycan-dependent anti-CD24 antibody radiopharmaceutical for solid tumors and a broader CXCR4 imaging platform.

Is Pentixapharm a public or private company?

Pentixapharm is a public company. It is classified as public and is currently operating.

When was Pentixapharm founded?

Pentixapharm was founded in 2024. It employs 11 to 50 people.

Where is Pentixapharm based?

Pentixapharm is headquartered in Würzburg, Germany, in the Europe region.

How does Pentixapharm make money?

One revenue line is on record: radiopharmaceutical Product Sales.

Does Pentixapharm have an API?

No public API is recorded for Pentixapharm.

What industry is Pentixapharm in?

Pentixapharm's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaPentixapharm Holding AG (PTPDF) Q3 2026 Earnings Call TranscriptPentixapharm Holding AG reported its Q3 and nine-month 2026 financial results on November 12, 2026, with CEO Dirk Pleimes and CTO Eric Merten presenting. The company raised about EUR 20.4 million in gross from a rights offering and private placement, and discussed preparation for the PANDA trial and its pipeline.PR NewswirePentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted termsPentixapharm Holding AG amended its 4.00% convertible bond with Eckert & Ziegler SE, extending the term to 31 December 2030 and raising the interest rate to 6.00% p.a. from 1 January 2027. The amendment increases financial flexibility by deferring repayment of EUR 5.0 million and allowing further drawdowns until mid-2030.FinanzNachrichten.deEQS-CMS: Pentixapharm Holding AG: Veröffentlichung gemäß § 50 WpHG mit dem Ziel der europaweiten VerbreitungPentixapharm Holding AG increased its share capital by issuing up to 11,020,212 new shares at EUR 1.85 each, raising up to EUR 11,020,212. The company also adjusted the conversion price of its 4% convertible bond from EUR 4.70 to EUR 4.50 per share, effective July 3, 2026.The future of tradingPentixapharm Cuts Bond Conversion Price to EUR 4.50 From EUR 4.70 per SharePentixapharm Holding cut the conversion price on its 4% 2024/2027 convertible bond to EUR 4.50 from EUR 4.70 per share. The adjustment, decided November 5, 2026, applies to all conversion exercises from July 3, 2026, following a capital increase.FinanzNachrichten.deOriginal-Research: Pentixapharm Holding AG (von BankM AG): KaufenPentixapharm Holding AG announced on 19 October 2026 that its Phase-3 study PANDA's first patient enrollment will be delayed to Q1 2027, and adjusted its 2026 loss forecast to about €13 million from €21.6 million. The company expects €3.7 million of the loss to be non-cash due to a BaFin finding, with funding through 2028 unchanged.FinanzNachrichten.deEQS-News: Pentixapharm Holding AG: Pentixapharm meldet Fortschritte bei der zulassungsrelevanten Phase-3-Studie PANDA und lädt am 12. November 2026 zum Q3-Webcast einPentixapharm reported progress on its Phase-3 PANDA study for [68Ga]Ga-PentixaFor, with the FDA having no concerns on the protocol and the central US ethics committee approving it. The first patient is expected in Q1 2027, and the company will host a Q3 webcast on November 12, 2026.The future of tradingPentixapharm Secures US Ethics Approval for PANDA Phase 3 TrialPentixapharm received US ethics approval for its PANDA Phase 3 trial, with first-patient enrollment expected in Q1 2027. The trial targets about 325 patients across over 10 US sites, and the FDA cleared the protocol in August 2026. A November 12, 2026 webcast will present third-quarter financial results and a PANDA progress update.FinanzNachrichten.deEQS-Adhoc: Pentixapharm Holding AG: Ergebnisprognose 2026 angehoben; Aufnahme des ersten Patienten in PANDA Phase-3-Studie nunmehr für das erste Quartal 2027 erwartetPentixapharm Holding AG's board raised its 2026 loss forecast to about EUR 13 million, down from EUR 21.6 million, citing cost shifts and reduced amortization. The first patient enrollment in the PANDA Phase-3 study is now expected in Q1 2027, with funding through 2028 unchanged.FinanzNachrichten.dePentixapharm: Bafin stellt Fehler im Konzernabschluss 2024 festBafin completed its audit of Pentixapharm and found multiple errors in the company's 2024 consolidated financial statements. The errors concern matters the company had already disclosed publicly in June 2026.FinanzNachrichten.deEQS-Adhoc: Pentixapharm Holding AG: Bafin schließt Bilanzkontrolle des Konzernabschlusses 2024 mit Fehlerfeststellung abBafin concluded the 2024 consolidated financial statements of Pentixapharm Holding AG were flawed, overstating intangible assets by €34.7 million and capital reserve by €21.6 million. The overstatement stems from a purchase price allocation and unfulfilled development project activation conditions. The board decided not to appeal.